OUTSOURCED PHARMA CONTENT COLLECTIONS
We’ve collected a series of editorials and articles that feature some frontline examples, and best practices, from a variety of CMC practitioners. These include narratives that readers will surely relate to on both a personal and professional level, as well as sound advice from consultants, and sage guidance from those with decades-long experience.
COVID-19 And Your Supply Chains: Analysis And Advice From Outsourced Pharma
The coronavirus pandemic has tossed together your drug development and manufacturing supply chains with a worldwide health and health-care challenge, national security concerns, and international and domestic politics. Outsourced Pharma Chief Editor Louis Garguilo has covered this convergence from the very beginning of the outbreak. This collection of his editorials and podcast will help you to think through your outsourcing strategy in the face of the outbreak of COVID-19, and offers some keen analysis and best practices. He suggests biotech and pharma companies take this moment in time to deeply reconsider geographic and other supply-chain risks to enhance decisions for maintaining the most reliable source of drugs and vaccines, and to openly ask and answer difficult questions. Download the eBook now.
Expert Advice For All Facets Of Managing Your External CMC Partners
More outsourcing needs to translate to better outsourcing – improved efficiencies, productivity, speed, and CDMO relationships. Easier said than done. But no internal function at a biotech or pharma company can do more to accomplishing these improvements than the CMC (chemistry, manufacturing and controls) group.
Outsourcing Trends For Cell & Gene Therapy
The cell and gene therapy sector’s focus on outsourcing is a major area of on-going concern due to the shortage of suitable manufacturing facilities and qualified outsourcing staff. This collection of articles weighs the economic benefits of outsourcing (i.e. productivity, efficiency, time-to-market, and quality gains) as well as best practices for selecting an outsourcing partner. Here you’ll find information about the current limitations associated with a complicated manufacturing process as well as existing and promising opportunities and developments needed to outsource most — if not all components — of the value chain.
Patents, Generics, And Innovative Drugs: New Ideas For Drug Development Within The U.S. Healthcare System
Partnerships between sponsor companies and contract manufacturers can take on endless variations. Louis Garguilo, Chief Editor of Outsourced Pharma explores several successful sponsor-CDMO relationships by talking to the participants involved in this free collection of articles.
Data Integrity In The Life Sciences
This eBook is a collection of articles from the Data Integrity In The Life Sciences series, the purpose of which is to highlight contemporary insights and relationships to key quality systems in order to elevate the most important topics and advance improvements in the collective quality culture.
Keeping Up With Continuous Manufacturing
The promise of continuous manufacturing seems almost limitless in its potential. But, what about the reality on the ground? Louis Garguilo, Chief Editor of Outsourced Pharma, looks at current continuous manufacturing initiatives underway and what’s slowing adoption.
The State Of Fill-Finish Services In Pharma
Outsourced Pharma’s Chief Editor, Louis Garguilo, takes a deep-dive into the current state of fill-finish services in the pharmaceutical outsourcing space. He talks to executives from both sponsor and CDMO companies and helps readers understand the current challenges in fill-finish, stakeholders’ role in improving outcomes, and potential future solutions.
Modeling Relationships With CDMOs
Partnerships between sponsor companies and contract manufacturers can take on endless variations. Louis Garguilo, Chief Editor of Outsourced Pharma explores several successful sponsor-CDMO relationships by talking to the participants involved.
Examining the Biopharma-CDMO Relationship with the Global Drug Industry
Are we dangerously reliant on outsourcing to China, and is this outsourcing without the good of U.S. patients in mind? Our drug development and manufacturing outsourcing industry can’t escape the ins-and-outs of geopolitical and global affairs. Learn more in this free collection of articles